Patents by Inventor Laura RHIEL

Laura RHIEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10676733
    Abstract: The present invention provides methods for the non-covalent surface display of proteins of interest (POI), in particular for Fc-domain containing proteins such as antibodies. The inventive method may be used to screen and select proteins of interest of a desired phenotype. The present invention further discloses polynucleotides and proteins and methods of producing the same, which may be used in carrying out the inventive method.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: June 9, 2020
    Assignee: Merck Patent GmbH
    Inventors: Laura Rhiel, Stefan Becker, Ralf Guenther, Bjoern Hock, Daniel Helman, Mira Toister-Achituv, Simon Krah
  • Publication number: 20190248907
    Abstract: The present invention provides antibodies and heterodimeric immunoglobulin molecules, which bind cMET with high affinity and can be used to target cMET expressing tumor cells. The present invention also discloses methods of generating anti-cMET antibody drug conjugates using the inventive antibodies or heterodimeric immunoglobulin molecules as disclosed herein.
    Type: Application
    Filed: September 14, 2017
    Publication date: August 15, 2019
    Applicant: MERCK PATENT GMBH
    Inventors: Achim DOERNER, Lars TOLEIKIS, Birgit PIATER, Laura RHIEL, Christine KNUEHL, Carolin SELLMANN, Simon KRAH
  • Patent number: 10183994
    Abstract: The invention relates to anti-TNF? antibodies which are engineered to exhibit a pH-sensitive antigen binding. The invention is preferably directed to anti-TNF? antibody adalimumab (Humira®) or biologically active variants and fragments thereof, wherein the original adalimumab antibody or variant or fragment thereof is engineered by modifications of amino acid sequence within the variable regions. Specifically, the invention relates to adalimumab or biologically active variants or fragments thereof, wherein the CDR domains are modified by replacing one or more amino acid residues by histidine residues.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: January 22, 2019
    Assignee: Merck Patent GmbH
    Inventors: Ralf Guenther, Stefan Becker, Laura Rhiel, Bjoern Hock, Christian Schroeter
  • Patent number: 10138477
    Abstract: The invention relates to a method for the production and non-covalent surface display of antibodies and derived fragments as well as molecule libraries based thereon on the surface of S. cerevisiae cells. The non-covalent manner of the surface display renders possible the selection of specific variants by means of high throughput screening and the subsequent switchable secretion of the selected binding molecule into the culture supernatant for biochemical characterization.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: November 27, 2018
    Assignee: MERCK PATENT GmbH
    Inventors: Ralph Guenther, Bjoern Hock, Stefan Becker, Laura Rhiel
  • Publication number: 20180298374
    Abstract: The present invention provides methods for the non-covalent surface display of proteins of interest (POI), in particular for Fc-domain containing proteins such as antibodies. The inventive method may be used to screen and select proteins of interest of a desired phenotype. The present invention further discloses polynucleotides and proteins and methods of producing the same, which may be used in carrying out the inventive method.
    Type: Application
    Filed: October 27, 2015
    Publication date: October 18, 2018
    Applicant: Merck Patent GmbH
    Inventors: Laura Rhiel, Stefan Becker, Ralf Guenther, Bjoern Hock, Daniel Helman, Mira Toister-Achituv, Simon Krah
  • Publication number: 20170226199
    Abstract: The invention relates to anti-TNFa antibodies which are engineered to exhibit a pH-sensitive antigen binding. The invention is preferably directed to anti-TNFa antibody adalimumab (Humira®) or biologically active variants and fragments thereof, wherein the original adalimumab antibody or variant or fragment thereof is engineered by modifications of amino acid sequence within the variable regions. Specifically, the invention relates to adalimumab or biologically active variants or fragments thereof, wherein the CDR domains are modified by replacing one or more amino acid residues by histidine residues.
    Type: Application
    Filed: June 26, 2015
    Publication date: August 10, 2017
    Applicant: Merck Patent GmbH
    Inventors: Ralf GUENTHER, Stefan BECKER, Laura RHIEL, Bjoern HOCK, Christian SCHROETER
  • Publication number: 20150337292
    Abstract: The invention relates to a method for the production and non-covalent surface display of antibodies and derived fragments as well as molecule libraries based thereon on the surface of S. cerevisiae cells. The non-covalent manner of the surface display renders possible the selection of specific variants by means of high throughput screening and the subsequent switchable secretion of the selected binding molecule into the culture supernatant for biochemical characterisation.
    Type: Application
    Filed: December 11, 2013
    Publication date: November 26, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Ralph GUENTHER, Bjoern HOCK, Stefan BECKER, Laura RHIEL